Copyright
©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Oct 27, 2010; 2(10): 367-373
Published online Oct 27, 2010. doi: 10.4254/wjh.v2.i10.367
Published online Oct 27, 2010. doi: 10.4254/wjh.v2.i10.367
Liver-specific therapies for metastases of neuroendocrine pancreatic tumors
Volker Fendrich, Nils Habbe, Detlef Klaus Bartsch, Department of Surgery, Philipps-University, Marburg D-35043, Germany
Patrick Michl, Department of Gastroenterology, Philipps-University, Marburg D-35043, Germany
Author contributions: Fendrich V, Michl P and Habbe N reviewed the literature and contributed to different sections of the manuscript; and Bartsch DK revised the manuscript.
Correspondence to: Volker Fendrich, MD, Department of Surgery, Philipps University Marburg, Baldingerstraße, Marburg D-35043, Germany. fendrich@med.uni-marburg.de
Telephone: +49-642-12862582 Fax: +49-642-12863851
Received: July 1, 2010
Revised: October 5, 2010
Accepted: October 12, 2010
Published online: October 27, 2010
Revised: October 5, 2010
Accepted: October 12, 2010
Published online: October 27, 2010
Abstract
The presence or development of liver metastases in patients with neuroendocrine pancreatic tumors is the most important prognostic factor. Liver resection, transplantation and many different therapeutic approaches are discussed in this special review.
Keywords: Liver metastasis; Neuroendocrine pancreatic tumor; Liver resection; Liver transplantation; Chemotherapy; Biotherapy